📇 Rhumatologue · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
16
16 articles ont été cités au moins 16fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 261
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
35
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
17
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Proteomic analysis of liver fibrosis reveals EFEMP1 as a new modulator of focal adhesion and migration of hepatic stellate cells
2025ArticleFASEB Journal
Proteomics analysis of liver fibrosis reveals Fibulin-3 as a new regulator of hepatic stellate cells
2024CongrèsEuropean-Association-for-the-Study-of-the-Liver Congress (EASL)
ADAMTS12 is a stromal modulator in chronic liver disease
2023ArticleFASEB Journal
Integration of miRNA‐regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Journal of cellular and molecular medicine · 2009
AbstractChemokines are the inflammatory mediators that modulate liver fibrosis, a common feature of chronic inflammatory liver diseases. CX3CL1/fractalkine is a membrane‐associated chemokine that requires step processing for chemotactic activity and has been recently implicated in liver disease. Here, we investigated the potential shedding activities involved in the release of the soluble chemotactic peptides from CX3CL1 in the injured liver. We showed an increased expression of the sheddases ADAM10 and ADAM17 in patients with chronic liver diseases that was associated with the severity of liver fibrosis. We demonstrated that hepatic stellate cells (HSC) were an important source of ADAM10 and ADAM17 and that treatment with the inflammatory cytokine inter‐feron‐γ induced the expression of CX3CL1 and release of soluble peptides. This release was inhibited by the metalloproteinase inhibitor batimastat; however, ADAM10/ADAM17 inhibitor GW280264X only partially affected shedding activity. By using selective tissue metalloprotease inhibitors and overexpression analyses, we showed that CX3CL1 was mainly processed by matrix metalloproteinase (MMP)‐2, a metalloprotease highly expressed by HSC. We further demonstrated that the CX3CL1 soluble peptides released from stimulated HSC induced the activation of the CX3CR1‐dependent signalling pathway and promoted chemoattraction of monocytes in vitro. We conclude that ADAM10, ADAM17 and MMP‐2 synthesized by activated HSC mediate CX3CL1 shedding and release of chemotactic peptides, thereby facilitating recruitment of inflammatory cells and paracrine stimulation of HSC in chronic liver diseases.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023 · Journal Article
Dekky B, Azar F, Bonnier D, Monseur C, et al.
Liver international : official journal of the International Association for the Study of the Liver · 2020 · Journal Article
Azar F, Courtet K, Dekky B, Bonnier D, et al.
Journal of cellular and molecular medicine · 2009 · Journal Article
Bourd-Boittin K, Basset L, Bonnier D, L'helgoualc'h A, et al.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Affiliations FR : Inserm · École des Hautes Études en Santé Publique · Institut de Recherche en Santé, Environnement et Travail
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
ArticleLiver International
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
International archives of allergy and applied immunology · 1989
The specificity of autoantibodies present in the serum of 151 patients with systemic lupus erythematosus (SLE) was investigated by ELISA using as antigen individual histones as well as 17 different core histone synthetic peptides. Many of the sera reacted with four terminal peptides (residues 1–21 and 130–135 of H3, 1–29 of H4 and 1–25 of H2B) while fewer reacted with internal peptides (residues 65–85 of H2A and 40–55 of H3). Of the 151 SLE sera, 88% reacted with one or more of the six core histone peptides whereas only 57% reacted with one or more of the complete core histone molecules. Antibodies to mononucleosomes from chicken erythrocytes were also prepared in rabbits. The rabbit antisera were tested by ELISA using as antigen chromatin subunits, native and denatured DNA, individual histones and 23 natural and synthetic peptides of histones. The antinucleosome antibodies were found to recognize the same peptide fragments as those recognized by the SLE sera.
Liver international : official journal of the International Association for the Study of the Liver · 2020
AbstractBackground & AimsActivation of hepatic stellate cells (HSC) is a critical process involved in liver fibrosis. Several miRNAs are implicated in gene regulation during this process but their exact and respective contribution is still incompletely understood. Here we propose an integrative approach of miRNA‐regulatory networks to predict new targets.MethodsmiRNA regulatory networks in activated HSCs were built using lists of validated miRNAs and the CyTargetLinker tool. The resulting graphs were filtered according to public transcriptomic data and the reduced graphs were analysed through GO annotation. A miRNA network regulating the expression of TIMP3 was further studied in human liver samples, isolated hepatic cells and mouse model of liver fibrosis.ResultsWithin the up‐regulated miRNAs, we identified a subnetwork of five miRNAs (miR‐21‐5p, miR‐222‐3p, miR‐221‐3p miR‐181b‐5p and miR‐17‐5p) that target TIMP3. We demonstrated that TIMP3 expression is inversely associated with inflammatory activity and IL1‐ß expression in vivo. We further showed that IL1‐ß inhibits TIMP3 expression in HSC‐derived LX‐2 cells. Using data from The Cancer Genome Atlas (TCGA), we showed that, in hepatocellular carcinoma (HCC), TIMP3 expression is associated with survival (P < .001), while miR‐221 (P < .05), miR‐222 (P < .01) and miR‐181b (P < .01) are markers for a poor prognosis.ConclusionsSeveral miRNAs targeting TIMP3 are up‐regulated in activated HSCs and down‐regulation of TIMP3 expression is associated with inflammatory activity in liver fibrosis and poor prognosis in HCC. The regulatory network including specific miRNAs and TIMP3 is therefore central for the evolution of chronic liver disease.
International archives of allergy and applied immunology · 1989 · Journal Article
Muller S, Bonnier D, Thiry M, Van Regenmortel MH